Rumpf K W, Barth M, Blech M, Kaiser H, Koop I, Arnold R, Scheler F
Klin Wochenschr. 1984 Apr 16;62(8):346-8. doi: 10.1007/BF01716252.
A muscular syndrome has been described in patients on clofibrate and fenofibrate therapy. The present paper describes four patients with impaired renal function in whom symptoms and signs of skeletal muscle damage developed during treatment with another clofibrinic acid derivative, bezafibrate. The syndrome was characterized by variable degrees of muscular cramps and paresis, excessive elevation of muscle enzymes in serum, myoglobinemia and myoglobinuria. Transient deterioration of renal function was also common. All patients had been overdosed with bezafibrate with regard to their renal function. It is concluded that bezafibrate like other lipid lowering agents of the clofibrate type may induce muscle damage, at least if doses are not adjusted to renal function. Extreme caution is warranted when treating patients with renal impairment with bezafibrate and strict dose adjustment to kidney function is necessary to avoid muscle damage.
已有报道称服用氯贝丁酯和非诺贝特治疗的患者会出现一种肌肉综合征。本文描述了4例肾功能受损的患者，他们在使用另一种氯贝酸衍生物苯扎贝特治疗期间出现了骨骼肌损伤的症状和体征。该综合征的特征为不同程度的肌肉痉挛和无力、血清中肌肉酶过度升高、肌红蛋白血症和肌红蛋白尿。肾功能短暂恶化也很常见。所有患者的苯扎贝特剂量相对于其肾功能来说都过量了。得出的结论是，苯扎贝特与其他氯贝丁酯类降脂药一样，可能会诱发肌肉损伤，至少在剂量未根据肾功能调整的情况下如此。在用苯扎贝特治疗肾功能损害患者时必须极度谨慎，并且有必要严格根据肾功能调整剂量以避免肌肉损伤。
